



iCo Therapeutics

iCo-008's is a human monoclonal antibody targeting eotaxin-1, a chemo-attractant for eosinophils and a ligand for chemokine receptor 3 (CCR3). iCo licensed the worldwide rights to all indications for iCo-008 from AstraZeneca/MedImmune. iCo-008 is also known as Bertilimumab or CAT-213.

Eotaxin-1 represents a well-established target for multiple allergic conditions. According to recent literature, eotaxin and interleukin-5 (IL-5) signaling pathways may need to be targeted in order to control the inflammation and airway hyper-responsiveness associated with severe asthma. New literature also implicates that the CCR3/Eotaxin-1 axis is a target for age-related macular degeneration.

POTENTIAL INDICATIONS

Ocular Markets:

Wet Age Related Macular Degeneration (wAMD)
Vernal & Atopic Keratoconjunctivitis

Systemic Markets (Out-licensed to Immune Pharmaceuticals):

Allergic rhinitis
Inflammatory Bowel Disease, Crohn's Disease
Food allergies
Severe Asthma

PRODUCT HIGHLIGHTS

Human monoclonal antibody targeting eotaxin-1
Good safety & significant clinical history
- Phase 1 & 2 (n=126)
Highly specific to human eotaxin-1
iCo-008 utilizes a targeted, highly specific biological approach
Eotaxin binds with high affinity to CCR3

CLINICAL HISTORY

Phase 1: (n=25) No serious adverse events

Phase 2: (n=101) Applied intranasally & topically to the eye

- Safe and well tolerated
- Evidence of efficacy in severe allergy indication: reduced post allergy nasal obstruction

UPCOMING MILESTONES

- ✓ Licensed systemic rights to Immune Pharmaceuticals US\$32+ Million while retaining ocular rights
- Pursuing non-dilutive funding of wAMD program

iCo-008: Human monoclonal antibody treating both the back and front of the eye

**WET AGE-RELATED
MACULAR DEGENERATION
(wAMD)**

- Afflicts the elderly
- Leads to rapid vision loss
- New literature implicates that CCR3/Eotaxin-1 axis is a target for AMD

**\$32 + M LICENSE WITH
IMMUNE PHARMA**

- License for systemic uses
- iCo retained WW exclusive rights to all ocular indications
- Upfront: \$500,000 cash, 600,000 IMMUNE shares, 200,000 IMMUNE warrants, 6.14% ownership stake (fully diluted basis) with preferential share features
- Up to **\$32M** in milestones
- Royalties on licensed products

760-777 Hornby St
Vancouver, BC Canada V6Z 1S4
604-602-9414

www.icotherapeutics.com